SG156524A1 - New compounds useful for the treatment of obesity, type ii diabetes and cns disorders - Google Patents

New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Info

Publication number
SG156524A1
SG156524A1 SG200604188-3A SG2006041883A SG156524A1 SG 156524 A1 SG156524 A1 SG 156524A1 SG 2006041883 A SG2006041883 A SG 2006041883A SG 156524 A1 SG156524 A1 SG 156524A1
Authority
SG
Singapore
Prior art keywords
obesity
diabetes
treatment
type
cns disorders
Prior art date
Application number
SG200604188-3A
Inventor
Gary Johansson
Annika Jenmalm-Jensen
Katarina Beierlein
Original Assignee
Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201925A external-priority patent/SE0201925D0/en
Priority claimed from SE0202181A external-priority patent/SE0202181D0/en
Priority claimed from SE0202908A external-priority patent/SE0202908D0/en
Priority claimed from SE0300357A external-priority patent/SE0300357D0/en
Application filed by Biovitrum Ab Publ filed Critical Biovitrum Ab Publ
Publication of SG156524A1 publication Critical patent/SG156524A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to compounds of the general formula (I), wherein P is sulfone or sulfonamide; and A, B, W, X, Y and R3 are defined in the description; to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, and/or CNS disorders, to achieve reduction of body weight and of body weight gain.
SG200604188-3A 2002-06-20 2003-06-19 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders SG156524A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
SE0201925A SE0201925D0 (en) 2002-06-20 2002-06-20 New compounds
SE0202181A SE0202181D0 (en) 2002-07-11 2002-07-11 New compounds
US40612002P 2002-08-26 2002-08-26
SE0202908A SE0202908D0 (en) 2002-10-01 2002-10-01 New compounds
US43401002P 2002-12-17 2002-12-17
SE0300357A SE0300357D0 (en) 2003-02-10 2003-02-10 New compounds
US46470103P 2003-04-23 2003-04-23

Publications (1)

Publication Number Publication Date
SG156524A1 true SG156524A1 (en) 2009-11-26

Family

ID=30004107

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200604188-3A SG156524A1 (en) 2002-06-20 2003-06-19 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Country Status (13)

Country Link
EP (1) EP1513828A1 (en)
CN (1) CN1662521A (en)
AU (1) AU2003243091A1 (en)
BR (1) BR0311952A (en)
CA (1) CA2486989A1 (en)
EA (2) EA008835B1 (en)
IL (1) IL165051A0 (en)
MX (1) MXPA04012914A (en)
NO (1) NO20050294L (en)
NZ (3) NZ552283A (en)
RS (1) RS111204A (en)
SG (1) SG156524A1 (en)
WO (1) WO2004000828A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0308696B8 (en) 2002-03-27 2021-05-25 Axovant Sciences Gmbh quinoline-derived compound, its preparation process, its pharmaceutical composition and its uses
SE0301446D0 (en) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
WO2005012254A1 (en) 2003-07-22 2005-02-10 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related therto
SE0302760D0 (en) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
KR20060127886A (en) * 2003-12-19 2006-12-13 바이오비트럼 에이비 Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
SE0303480D0 (en) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
EP1737845A4 (en) * 2004-04-13 2010-07-21 Synta Pharmaceuticals Corp Disalt inhibitors of il-12 production
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
AR054044A1 (en) * 2005-05-23 2007-05-30 Astrazeneca Ab CHROMAN AND TETRAHYDRONAFTALENE DERIVATIVES AS RECEPTOR MODULATORS 5 - HT6; INTERMEDIARIES IN THEIR PREPARATION; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPELO IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CNS AND OBESITY DISEASES.
US7582767B2 (en) 2005-06-17 2009-09-01 Biovitrum Ab (Publ.) Substituted sulphonamide compound and uses thereof
US20090221644A1 (en) * 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
CN103819416A (en) 2005-10-07 2014-05-28 埃克塞里艾克西斯公司 N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
NZ567285A (en) 2005-11-03 2010-06-25 Hoffmann La Roche Arylsulfonylchromans as 5-HT6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
WO2007147771A2 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof
BRPI0713502A2 (en) 2006-06-20 2012-03-13 F. Hoffmann-La Roche Ag arylsulfonamidyl tetraline derivatives and uses of these
JP2009541249A (en) 2006-06-20 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー Arylsulfonylnaphthalene derivatives and uses thereof
TWI433839B (en) 2006-08-11 2014-04-11 Neomed Inst New benzimidazole derivatives 290
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US7888662B2 (en) 2008-06-20 2011-02-15 Varian Semiconductor Equipment Associates, Inc. Ion source cleaning method and apparatus
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
AR082889A1 (en) * 2011-05-09 2013-01-16 Forma Therapeutics Inc COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT
WO2015090233A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
MX2017016413A (en) 2015-06-12 2018-08-01 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder.
MX2018000465A (en) 2015-07-15 2018-09-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease.
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments
WO2001032660A1 (en) * 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
WO2001032646A2 (en) * 1999-11-05 2001-05-10 Smithkline Beecham P.L.C. Sulfonamide derivatives
WO2002032863A1 (en) * 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
WO2002098857A1 (en) * 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag New indole derivatives with 5-ht6 receptor affinity
WO2002100822A1 (en) * 2001-06-11 2002-12-19 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB947606A (en) * 1961-04-10 1964-01-22 Ici Ltd N-substituted piperazines
US4808595A (en) * 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
DK0689536T3 (en) * 1993-03-16 2001-07-30 Pfizer naphtahlene
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
AU2001264566A1 (en) * 2000-05-05 2001-11-20 Cor Therapeutics, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
AU2001259707A1 (en) * 2000-06-14 2001-12-24 Warner Lambert Company 6,5-fused bicyclic heterocycles
AU2002303061B2 (en) * 2001-05-11 2009-01-29 Biovitrum Ab (Publ) Novel, arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments
WO2001032660A1 (en) * 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
WO2001032646A2 (en) * 1999-11-05 2001-05-10 Smithkline Beecham P.L.C. Sulfonamide derivatives
WO2002032863A1 (en) * 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
WO2002098857A1 (en) * 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag New indole derivatives with 5-ht6 receptor affinity
WO2002100822A1 (en) * 2001-06-11 2002-12-19 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
METHVIN ISAAC ET AL.: '6-Bicyclopiperazinyl-1-arylsulfonylindoles and 6-bicyclopiperidinyl-1-arylsulfonylindoles derivatives as novel, potent and selective 5-HT6 receptor antagonists' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS vol. 10, no. 15, 2000, pages 1719 - 1721 *

Also Published As

Publication number Publication date
AU2003243091A1 (en) 2004-01-06
IL165051A0 (en) 2005-12-18
RS111204A (en) 2006-12-15
NZ552283A (en) 2008-07-31
EA008835B1 (en) 2007-08-31
CA2486989A1 (en) 2003-12-31
NO20050294L (en) 2005-02-04
NZ552282A (en) 2008-07-31
MXPA04012914A (en) 2005-03-31
NZ536600A (en) 2007-08-31
EP1513828A1 (en) 2005-03-16
EA200600975A1 (en) 2006-10-27
BR0311952A (en) 2005-04-19
CN1662521A (en) 2005-08-31
EA200500054A1 (en) 2005-06-30
EA011581B1 (en) 2009-04-28
WO2004000828A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
SG156524A1 (en) New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
YU98003A (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
SE0403006D0 (en) New compounds
DE602004011394D1 (en) Thiazolderivate
AP2088A (en) Phenethanolamine derivatives for treatment of respiratory diseases
GB0225475D0 (en) Therapeutic agents
MXPA04002405A (en) Phenethanolamine derivatives for treatment of respiratory diseases.
AU2804400A (en) Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
WO2004037768A3 (en) Phenethanolamine derivatives
WO2001081310A8 (en) 1-aroyl-piperidinyl benzamidines
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
ATE381537T1 (en) FORMANILIDE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MY143390A (en) Sulfonamide derivatives for the treatment of diseases.
MXPA04005886A (en) Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands.
GB0102672D0 (en) Compounds
UA83233C2 (en) Substituted 2-aminotetralin for the treatment of depression
MD2447F2 (en) Pharmaceutical composition, use thereof and methods of treatment of cephalalgia, migraine, sickness and vomiting
NO20052699L (en) 4 (phenylpiperazinylmethyl) benzamide derivatives and their use in the treatment of pain and gastrointestinal disorders.
SE0202429D0 (en) Novel Compounds
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
WO2005110413A3 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
DE60233350D1 (en) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
WO2004037166A3 (en) Therapeutic guanidines